A Cyclodiaryliodonium NOX Inhibitor for the Treatment of Pancreatic Cancer via Enzyme‐Activatable Targeted Delivery by Sulfated Glycosaminoglycan Derivatives (Adv. Healthcare Mater. 17/2023)

Nanoparticle‐Drug Conjugates To combat pancreatic cancer with a dismal prognosis, a self‐assembled nanoparticle‐drug conjugate is synthesized in article 2203011 by Peng Huang, Shijun Wen, Jiang Yang, and co‐workers. Based on chemically‐modified sulfated glycosaminoglycan derivatives, a nanoparticle‐drug conjugate (NDC) efficiently encapsulates a cyclodiaryliodonium NOX inhibitor from pooled screening, enabling hyaluronidase‐activatable release, and facilitates CD44‐targeted cellular trafficking to elicit anti‐cancer efficacy with a good safety profile.